Enriched clinical annotations |
For each of the clinical annotations, we tested whether it was enriched in the set of arrays in which the module is significantly induced (or repressed). Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of induced (or repressed) module's arrays in which they appear. We also show the fraction of the module's induced (or repressed) arrays with the given annotation ('Hits (%)' column). For completeness, we also list the total number of relevant induced arrays in the module ('Module hits in category' column), total number of arrays in the compendium in which the corresponding annotation is present ('Arrays in annotation' column), and the total number of relevant arrays in the compendium ('Arrays' column). Note that the 'relevant' arrays may be different for each annotation, since it includes only arrays in which the annotation was relevant (i.e., present or not present) and excludes arrays where the value of the annotation was not known. Rows that correspond to annotations that were enriched in the induced arrays of the module have a red background, while rows corresponding to annotations enriched in the repressed arrays have a green background. For each annotation, we also list the other modules in which it was enriched. |
Clinical annotation |
Category |
P-value |
Hits |
Hits(%) |
Module hits in category |
Arrays in annotation |
Arrays |
Hematologic samples (Stimulated PBMC*) |
Stimulated PBMC* |
3.8e-52 |
114 |
28.5 |
400 |
152 |
1945 |
Lymphocytes (Stimulated PBMC*) |
Stimulated PBMC* |
3.8e-52 |
114 |
28.5 |
400 |
152 |
1945 |
Primary blood mononuclear cells (Stimulated PBMC*) |
Stimulated PBMC* |
3.8e-52 |
114 |
28.5 |
400 |
152 |
1945 |
Hematologic samples and cell lines (Stimulated PBMC*) |
Stimulated PBMC* |
2.2e-39 |
114 |
28.5 |
400 |
182 |
1945 |
Monocytes (Stimulated PBMC*) |
Stimulated PBMC* |
2.2e-39 |
114 |
28.5 |
400 |
182 |
1945 |
Stimulated immune cells (Stimulated PBMC*) |
Stimulated PBMC* |
1.2e-32 |
92 |
23 |
400 |
143 |
1945 |
Hematologic cancer and cell line (Stimulated PBMC) |
Stimulated PBMC |
1.4e-22 |
30 |
63.8 |
47 |
30 |
182 |
Macrophages (Stimulated PBMC) |
Stimulated PBMC |
1.4e-22 |
30 |
63.8 |
47 |
30 |
182 |
Cancer and cell line (Liver cancer) |
Liver cancer |
3.8e-15 |
63 |
96.9 |
65 |
126 |
207 |
Cancer (B lymphoma*) |
B lymphoma* |
1.7e-10 |
78 |
19.5 |
400 |
200 |
1945 |
Hematologic cancer (B lymphoma*) |
B lymphoma* |
1.7e-10 |
78 |
19.5 |
400 |
200 |
1945 |
B cells (B lymphoma*) |
B lymphoma* |
2.8e-10 |
86 |
21.5 |
400 |
231 |
1945 |
Lymphocytes (B lymphoma*) |
B lymphoma* |
1.1e-09 |
88 |
22 |
400 |
244 |
1945 |
Cancer and cell line (B lymphoma*) |
B lymphoma* |
7.7e-09 |
78 |
19.5 |
400 |
214 |
1945 |
Hematologic cancer and cell line (B lymphoma*) |
B lymphoma* |
7.7e-09 |
78 |
19.5 |
400 |
214 |
1945 |
Cell line (B lymphoma) |
B lymphoma |
4.4e-08 |
13 |
21.6 |
60 |
14 |
245 |
Lung carcinoid (Lung cancer) |
Lung cancer |
4.9e-08 |
17 |
22.0 |
77 |
20 |
276 |
B. petrussis stimulated immune cells (Stimulated PBMC) |
Stimulated PBMC |
5.7e-08 |
30 |
85.7 |
35 |
67 |
144 |
Liver tissue (Liver cancer*) |
Liver cancer* |
9.7e-08 |
68 |
17 |
400 |
187 |
1945 |
CNS tissue, cancer or cell line (Various tumors) |
Various tumors |
1.7e-07 |
20 |
29.4 |
68 |
21 |
154 |
Cancer (Liver cancer) |
Liver cancer |
1.8e-07 |
53 |
81.5 |
65 |
115 |
207 |
Acute leukemia (Leukemia*) |
Leukemia* |
3.9e-07 |
62 |
12.6 |
492 |
141 |
1945 |
Cancer and cell line (Leukemia*) |
Leukemia* |
3.9e-07 |
62 |
12.6 |
492 |
141 |
1945 |
Cancer (Leukemia*) |
Leukemia* |
3.9e-07 |
62 |
12.6 |
492 |
141 |
1945 |
Hematologic cancer and cell line (Leukemia*) |
Leukemia* |
3.9e-07 |
62 |
12.6 |
492 |
141 |
1945 |
Hematologic cancer (Leukemia*) |
Leukemia* |
3.9e-07 |
62 |
12.6 |
492 |
141 |
1945 |
Hematologic samples and cell lines (Leukemia*) |
Leukemia* |
3.9e-07 |
62 |
12.6 |
492 |
141 |
1945 |
Leukemia (Leukemia*) |
Leukemia* |
3.9e-07 |
62 |
12.6 |
492 |
141 |
1945 |
Leukemia or leukemia cell line (Leukemia*) |
Leukemia* |
3.9e-07 |
62 |
12.6 |
492 |
141 |
1945 |
Monocytes (Leukemia*) |
Leukemia* |
3.9e-07 |
62 |
12.6 |
492 |
141 |
1945 |
Hepatitis infected liver (Liver cancer*) |
Liver cancer* |
4.1e-07 |
58 |
14.5 |
400 |
156 |
1945 |
Non-tumor liver tissue (Liver cancer) |
Liver cancer |
4.3e-07 |
42 |
60.8 |
69 |
76 |
207 |
Cell line (Breast cancer) |
Breast cancer |
5.0e-07 |
19 |
50 |
38 |
30 |
152 |
Liver tissue, cancer or cell line (Liver cancer*) |
Liver cancer* |
9.9e-07 |
68 |
17 |
400 |
197 |
1945 |
Lymphoma (Various tumors) |
Various tumors |
2.3e-06 |
6 |
100 |
6 |
20 |
154 |
Breast cancer cell line (Breast cancer) |
Breast cancer |
2.8e-06 |
13 |
34.2 |
38 |
17 |
152 |
Diffuse large B cell lymphoma - DLBCL (Various tumors) |
Various tumors |
3.9e-06 |
5 |
83.3 |
6 |
11 |
154 |
Diffuse large B cell lymphoma tumor or cell line (Various tumors) |
Various tumors |
3.9e-06 |
5 |
83.3 |
6 |
11 |
154 |
Liver cancer cell line (Liver cancer) |
Liver cancer |
5.6e-06 |
10 |
15.3 |
65 |
10 |
207 |
B cells (Various tumors) |
Various tumors |
6.0e-06 |
6 |
100 |
6 |
23 |
154 |
Gram negative bacteria stimulated immune cells (Stimulated PBMC) |
Stimulated PBMC |
9.3e-06 |
30 |
85.7 |
35 |
78 |
144 |
Activated B like DLBCL (B lymphoma) |
B lymphoma |
9.7e-06 |
22 |
25 |
88 |
30 |
245 |
CNS cancer or cell line (Various tumors) |
Various tumors |
1.8e-05 |
15 |
22.0 |
68 |
16 |
154 |
CNS tumor (Various tumors) |
Various tumors |
1.8e-05 |
15 |
22.0 |
68 |
16 |
154 |
Lymphocytes (Various tumors) |
Various tumors |
2.2e-05 |
6 |
100 |
6 |
28 |
154 |
Monocytes (Various tumors) |
Various tumors |
2.2e-05 |
6 |
100 |
6 |
28 |
154 |
T cells (B lymphoma) |
B lymphoma |
4.0e-05 |
7 |
11.6 |
60 |
7 |
245 |
Lipopolysaccharide (LPS) stimulated immune cells (Stimulated PBMC) |
Stimulated PBMC |
4.1e-05 |
21 |
22.5 |
93 |
21 |
144 |
Female hormonal cancer cell line (Breast cancer) |
Breast cancer |
4.3e-05 |
11 |
28.9 |
38 |
15 |
152 |
Hematologic cancer and cell line (Various tumors) |
Various tumors |
4.3e-05 |
6 |
100 |
6 |
31 |
154 |
Hematologic cancer (Various tumors) |
Various tumors |
4.3e-05 |
6 |
100 |
6 |
31 |
154 |
Primary blood mononuclear cells (Various tumors) |
Various tumors |
4.3e-05 |
6 |
100 |
6 |
31 |
154 |
Cell line (Liver cancer) |
Liver cancer |
4.6e-05 |
10 |
15.3 |
65 |
11 |
207 |
Hepatocellular carcinoma (Liver cancer) |
Liver cancer |
5.1e-05 |
46 |
70.7 |
65 |
104 |
207 |
Hematologic samples and cell lines (Various tumors) |
Various tumors |
0.0001 |
6 |
100 |
6 |
37 |
154 |
Hematologic samples (Various tumors) |
Various tumors |
0.0001 |
6 |
100 |
6 |
37 |
154 |
Adenocarcinoma (Liver cancer) |
Liver cancer |
0.0001 |
43 |
66.1 |
65 |
97 |
207 |
Breast tissue or cancer (NCI60) |
NCI60 |
0.0001 |
4 |
23.5 |
17 |
4 |
139 |
Female hormonal tissue or cancer (NCI60) |
NCI60 |
0.0001 |
4 |
23.5 |
17 |
4 |
139 |
Primary blood mononuclear cells (B lymphoma) |
B lymphoma |
0.0001 |
10 |
16.6 |
60 |
14 |
245 |
Cancer and cell line (Various tumors*) |
Various tumors* |
0.0002 |
43 |
8.7 |
492 |
105 |
1945 |
Cancer (Various tumors*) |
Various tumors* |
0.0002 |
43 |
8.7 |
492 |
105 |
1945 |
Fast doubling (20-40) cell lines (NCI60) |
NCI60 |
0.0003 |
34 |
94.4 |
36 |
90 |
122 |